Danaher (DHR) Stock
Diversified science company for life sciences and diagnostics. Here's the price, business snapshot, and what's worth knowing about Danaher in October 2026.
Danaher Corporation (DHR) is a diversified science and technology company focused on life sciences, diagnostics and environmental & applied solutions. It supplies instruments, consumables, software and services used by research laboratories, hospitals and industrial customers worldwide. With a market capitalisation of about $155.94 billion, Danaher combines organic R&D-driven growth with disciplined acquisitions and operational rigor (the Danaher Business System) to drive recurring revenue and margin expansion. Investors often watch its exposure to healthcare spending, diagnostic cycles and capital-equipment demand. Strengths include a broad product portfolio, strong cash generation and a track record of integrating acquisitions; risks include execution on M&A, regulatory changes, cyclicality in capital spending and currency swings. Valuation can be premium given its defensive characteristics, but future returns are uncertain. This is general educational information, not personal investment advice — consider your goals and consult an authorised adviser before making investment decisions.
Why It’s Moving
Danaher Leadership Transition and Biotech Momentum Drive Analyst Optimism
- Julie Sawyer Montgomery has officially assumed the roles of President and Chief Executive Officer and joined the Board of Directors, effective October 1, 2026, fulfilling a previously announced succession plan.
- The Biotechnology segment reported 4% sales growth, providing a solid foundation for the company's performance, though analysts note that tough year-over-year comparisons and shipment timing remain potential headwinds to maintaining this pace.
- Broader interest in healthtech innovation remains high, with strong sector performance over recent quarters supporting renewed investor focus on medical technology leaders like Danaher.
Danaher Leadership Transition and Biotech Momentum Drive Analyst Optimism
- Julie Sawyer Montgomery has officially assumed the roles of President and Chief Executive Officer and joined the Board of Directors, effective October 1, 2026, fulfilling a previously announced succession plan.
- The Biotechnology segment reported 4% sales growth, providing a solid foundation for the company's performance, though analysts note that tough year-over-year comparisons and shipment timing remain potential headwinds to maintaining this pace.
- Broader interest in healthtech innovation remains high, with strong sector performance over recent quarters supporting renewed investor focus on medical technology leaders like Danaher.
Sixth Month Growth Performance
When is the next earnings date for Danaher (DHR)?
Danaher Corporation has a confirmed upcoming earnings report scheduled for October 21, 2026, before market opens. This release will cover the company's third quarter fiscal results for the period ending in September 2026. Investors should note that this date aligns with the firm's historical pattern of reporting in late October following the summer quarter.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Danaher stock with a target price of $251.45, indicating good potential for growth.
Financial Health
Danaher is performing well with strong revenue and profit margins, indicating good financial health.
Dividend
Danaher's low dividend yield of 0.67% makes it less appealing for those seeking dividend income. If you invested $1000 you would be paid $6.70 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring Revenue Engine
Consumables and service contracts support predictable recurring revenue and cash flow, though demand can vary with spending cycles.
Global Healthcare Reach
A broad international footprint offers diversification across markets, while currency moves and regional regulation remain potential headwinds.
Innovation & M&A
R&D and targeted acquisitions expand capabilities and addressable markets, but integration and valuation risks deserve attention.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
